Cryoport, Inc. (CYRX) - Stock Analysis
Last updated: May 9, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q1 2026 revenue grew 16% YoY, commercial cell and gene therapy revenue grew 26%, full-year revenue guidance was raised to $192M-$196M, and the stock is up about 37% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Liquidity Cushion ⢠Operating Losses ⢠Weak Cash Flow CryoPort has strong liquidity and manageable leverage, but persistent operating losses and weak cash conversion make the stock more of a balance-sheet story than a durable earnings story.
Price Behavior
Key Price Behavior Insights: ⢠Breakout intact ⢠Momentum extended ⢠Support nearby Support Level: $12.20-$12.70 Resistance Level: $13.60 CYRX is still constructive after a breakout and higher-highs/higher-lows trend over the last month, but the sharp run has left it stretched and vulnerable to a pullback unless $12.20-$12.70 holds above the $10.20-$10.40 breakout zone.
Sentiment & News
Key News Insights: ⢠Revenue beat ⢠Guidance raised ⢠Broad-based growth Cryoport beat revenue expectations with broad-based 16% growth and raised 2026 guidance, even as its Q1 loss widened slightly versus estimates.
AI Summary
CYRX is now a âprove-itâ story: strong balance-sheet liquidity and accelerating CGT-led revenue growth are real positives, but the stock only works if that growth finally converts into operating leverage and positive cash flow, because persistent burn and a stretched post-breakout share price leave little room for execution missteps.
Description
Cryoport, Inc. provides temperature-controlled logistics and related services for life sciences customers across the Americas, Europe, the Middle East, Africa, and Asia Pacific. Its offerings include shipment management software, condition-monitoring and tracking tools, cryogenic transport equipment, and storage and handling services for biological materials. The company serves the biopharma, animal health, and human reproductive medicine markets and was founded in 1999 in Brentwood, Tennessee.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 6 | May 13 | CYRX | Cryoport, Inc. | Q1 2026 revenue grew 16% YoY, commercial cell and gene therapy revenue grew 26%, full-year revenue guidance was raised to $192M-$196M, and the stock is up about 37% over 21 trading days. | Active | +2.8% |